邮件订阅 RSS
刘萧, 杨楠, 吴守媛, 郭强强, 刘辉, 孙雅佳, 王健健, 周奇, 王子君, 史乾灵, 赵思雅, 李沁原, 罗旭飞, 吕萌, 宋旭萍, 陈耀龙. 2019年期刊公开发表的中国临床实践指南文献调查与评价——引文分析[J]. 协和医学杂志, 2021, 12(6): 1016-1021. DOI: 10.12290/xhyxzz.2021-0624
引用本文: 刘萧, 杨楠, 吴守媛, 郭强强, 刘辉, 孙雅佳, 王健健, 周奇, 王子君, 史乾灵, 赵思雅, 李沁原, 罗旭飞, 吕萌, 宋旭萍, 陈耀龙. 2019年期刊公开发表的中国临床实践指南文献调查与评价——引文分析[J]. 协和医学杂志, 2021, 12(6): 1016-1021. DOI: 10.12290/xhyxzz.2021-0624
shu
LIU Xiao, YANG Nan, WU Shouyuan, GUO Qiangqiang, LIU Hui, SUN Yajia, WANG Jianjian, ZHOU Qi, WANG Zijun, SHI Qianling, ZHAO Siya, LI Qinyuan, LUO Xufei, LYU Meng, SONG Xuping, CHEN Yaolong. Investigation and Evaluation of Chinese Clinical Practice Guidelines Published in Medical Journals in 2019: Analysis of the Evidence[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 1016-1021. DOI: 10.12290/xhyxzz.2021-0624
Citation: LIU Xiao, YANG Nan, WU Shouyuan, GUO Qiangqiang, LIU Hui, SUN Yajia, WANG Jianjian, ZHOU Qi, WANG Zijun, SHI Qianling, ZHAO Siya, LI Qinyuan, LUO Xufei, LYU Meng, SONG Xuping, CHEN Yaolong. Investigation and Evaluation of Chinese Clinical Practice Guidelines Published in Medical Journals in 2019: Analysis of the Evidence[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 1016-1021. DOI: 10.12290/xhyxzz.2021-0624
shu

2019年期刊公开发表的中国临床实践指南文献调查与评价——引文分析

Investigation and Evaluation of Chinese Clinical Practice Guidelines Published in Medical Journals in 2019: Analysis of the Evidence

    摘要
  • 摘要:
      目的  调查2019年期刊公开发表的中国临床实践指南推荐意见的证据引用现状，为合理利用研究证据支撑指南推荐意见提供参考。
      方法  系统检索并筛选2019年期刊公开发表的中国临床实践指南，纳入有明确推荐意见、证据质量分级和相应分级说明的指南，提取指南推荐意见的引文信息并对其进行分析。
      结果  共纳入指南31篇(中文29篇，英文2篇)，包含568条推荐意见(平均每篇指南包含18条推荐意见)和3126篇引文，其中2541条引文作为证据在指南推荐意见说明中呈现(此类引文，下文简称“证据”)。平均每篇指南引用82篇证据，平均每条推荐意见引用4篇证据。证据来源位居前3位的国家依次为中国(28.8%)、美国(25.9%)和英国(7.0%)。发表于近5年的证据仅占比39.2%(995/2541)。证据文献类型主要为随机对照试验(26.9%)，系统评价仅占比12.0%。
      结论  2019年期刊公开发表的中国指南，存在未明确列出推荐意见及对支撑推荐意见的证据引用不全面、实效性差等问题。指南制订者应合理利用当前可得的研究证据，进一步提高我国临床实践指南的制订质量。

     

    Abstract:
      Objective  To investigate the current status of evidence of recommendations contained in Chinese clinical practice guidelines published in journals in 2019, so as to provide reference for the use of evidence for Chinese guidelines in the future.
      Methods  We searched and analyzed information on Chinese guidelines published in 2019 with clear recommendations, grading of evidence quality and corresponding instructions of grading, as well as information on citations supporting the recommendations.
      Results  A total of 31 guidelines (29 Chinese guidelines and 2 English guidelines) containing 568 recommendations and 3126 references were included. Each guideline included an average of 18 recommendations. Of these, 2541 references were presented as evidence in the statements of guideline recommendation(such references are referred to as "evidence" hereafter). The average number of evidence was 82 in each guideline and every recommendation has 4 pieces of evidence. The top three countries where the evidence was from were China (28.8%), the United States (25.9%), and the United Kingdom (7.0%). Only 39.2% (995/2541) of the evidence was published in the last 5 years. The most common type of evidence for guidelines was randomized controlled trials (26.9%). The citation of systematic reviews was only 12.0%.
      Conclusions  Most of the Chinese guidelines published in 2019 did not have clear and unambiguous recommendations. Those guidelines with clear recommendations had incomplete and untimely evidence citations. Guideline developers should strengthen the rational use of currently available research evidence.

     

    • HTML全文
    • 参考文献(19)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回